Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 10/20 | 1.00 |
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | HTR5A | P47898 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norcisapride SCHEMBL593405 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL3319911 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL8245159 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL3317329 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Ticalopride SCHEMBL17208 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9790000 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9789990 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9789995 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Ticalopride SCHEMBL6847230 | 0.92 | HTR4 (0.85) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Water SCHEMBL9721747 | 0.89 | HTR4 (0.80) | HTR4HTR3AHTR3EHTR3BHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | claimed |
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524736-B2 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | ARMETHEON, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-1919909-B1 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARMETHEON INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2194053-B1 | Methoxy piperidine derivatives for use inr the treatment of gastrointestinal and central nervous system disorders | ARMETHEON INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130040987-A1 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARMETHEON, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138204-B2 | Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts | ARYX THERAPEUTICS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2194053-A1 | Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders | Aryx Therapeutics, Inc. (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | DONG-A-PHARM. CO., LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-5130312-A | Gastrointestinal motility stimulators | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-07-14 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-5041454-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-08-20 | — | — | US | disclosed |
| US-4990521-A | Treating diarhea | JANSSEN PHARMACEUTICA (BE) | 1991-02-05 | — | — | US | disclosed |
| US-4975439-A | Gastrointestinal motility stimulating properties | JANSSEN PHARMACEUTICAL N.V. (BE) | 1990-12-04 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| US-4906643-A | Substituted N-(3-hydroxy-4-piperidinyl)benzamides as gastrointestinal agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-03-06 | — | — | US | disclosed |
| EP-0251417-A2 | 4-(aroylamino) piperidinebutanamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-01-07 | — | — | EP | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040987-A1 | Stereoisomeric Compounds and Methods for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 70/4885HTR3A 315/4885HTR3E 407/4885 |
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | HTR4, HTR1A, TPH1 | HTR4 1/4885HTR3A 26/4885HTR3E 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.